-
1
-
-
79958043675
-
-
National Cancer Institute Accessed August 26, 2011
-
National Cancer Institute. SEER Cancer Statistics Review 1975-2008. http://seer.cancer.gov/statistics/. Accessed August 26, 2011.
-
SEER Cancer Statistics Review 1975-2008
-
-
-
2
-
-
85081792750
-
-
National Cancer Institute Accessed August 26, 2011
-
National Cancer Institute. A Snapshot of Lymphoma. http://www.cancer. gov/aboutnci/servingpeople/snapshots/lymphoma.pdf. Accessed August 26, 2011.
-
A Snapshot of Lymphoma
-
-
-
3
-
-
30144443996
-
Lymphoma incidence patterns by WHO subtype in the United States 1992-2001
-
Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
-
(2006)
Blood
, vol.107
, Issue.1
, pp. 265-276
-
-
Morton, L.M.1
Wang, S.S.2
Devesa, S.S.3
Hartge, P.4
Weisenburger, D.D.5
Linet, M.S.6
-
5
-
-
0037394103
-
Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-hodgkin's lymphoma
-
Pettengell R, Linch D, Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-hodgkin's lymphoma. Br J Haematol. 2003;121(1):44-48.
-
(2003)
Br J Haematol
, vol.121
, Issue.1
, pp. 44-48
-
-
Pettengell, R.1
Linch, D.2
-
6
-
-
24644500086
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
-
Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033.
-
(2005)
J Clin Oncol
, vol.23
, Issue.22
, pp. 5027-5033
-
-
Sehn, L.H.1
Donaldson, J.2
Chhanabhai, M.3
-
7
-
-
79951816939
-
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America
-
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
-
(2011)
Clin Infect Dis
, vol.52
, Issue.4
-
-
Freifeld, A.G.1
Bow, E.J.2
Sepkowitz, K.A.3
-
8
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera international trial (MInT) group
-
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 2006;7(5):379-391.
-
(2006)
Lancet Oncol
, vol.7
, Issue.5
, pp. 379-391
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
-
9
-
-
38549147027
-
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
-
German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
-
Pfreundschuh M, Schubert J, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
-
(2008)
Lancet Oncol
, vol.9
, Issue.2
, pp. 105-116
-
-
Pfreundschuh, M.1
Schubert, J.2
Ziepert, M.3
-
10
-
-
34547670214
-
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
-
Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158-3167.
-
(2007)
J Clin Oncol
, vol.25
, Issue.21
, pp. 3158-3167
-
-
Kuderer, N.M.1
Dale, D.C.2
Crawford, J.3
Lyman, G.H.4
-
11
-
-
33745989223
-
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
-
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
-
(2006)
J Clin Oncol
, vol.24
, Issue.19
, pp. 3187-3205
-
-
Smith, T.J.1
Khatcheressian, J.2
Lyman, G.H.3
-
12
-
-
70450159652
-
Pegfilgrastim-a health economic model to assess overall cost-effectiveness
-
Borget I, Di Palma M, Leonard R. Pegfilgrastim-a health economic model to assess overall cost-effectiveness. Eur J Hospital Pharm Prac. 2009;15:58-61.
-
(2009)
Eur J Hospital Pharm Prac
, vol.15
, pp. 58-61
-
-
Borget, I.1
Di Palma, M.2
Leonard, R.3
-
13
-
-
41549115442
-
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
-
Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11(2):172-179.
-
(2008)
Value Health
, vol.11
, Issue.2
, pp. 172-179
-
-
Eldar-Lissai, A.1
Cosler, L.E.2
Culakova, E.3
Lyman, G.H.4
-
14
-
-
64249170087
-
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
-
Lyman G, Lalla A, Barron R, Dubois RW. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25(2):401-411.
-
(2009)
Curr Med Res Opin
, vol.25
, Issue.2
, pp. 401-411
-
-
Lyman, G.1
Lalla, A.2
Barron, R.3
Dubois, R.W.4
-
15
-
-
66949127931
-
Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States
-
Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009;31(5):1092-1104.
-
(2009)
Clin Ther
, vol.31
, Issue.5
, pp. 1092-1104
-
-
Lyman, G.H.1
Lalla, A.2
Barron, R.L.3
Dubois, R.W.4
-
16
-
-
70349897133
-
The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK
-
Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193-205.
-
(2009)
Appl Health Econ Health Policy
, vol.7
, Issue.3
, pp. 193-205
-
-
Liu, Z.1
Doan, Q.V.2
Malin, J.3
Leonard, R.4
-
17
-
-
60349114096
-
Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy
-
Ramsey SD, Liu Z, Boer R, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12(2):217-225.
-
(2009)
Value Health
, vol.12
, Issue.2
, pp. 217-225
-
-
Ramsey, S.D.1
Liu, Z.2
Boer, R.3
-
18
-
-
67649126886
-
Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients
-
Danova M, Chiroli S, Rosti G, Doan QV. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori. 2009;95(2):219-226.
-
(2009)
Tumori
, vol.95
, Issue.2
, pp. 219-226
-
-
Danova, M.1
Chiroli, S.2
Rosti, G.3
Doan, Q.V.4
-
19
-
-
0042914721
-
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma
-
Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3041-3050.
-
(2003)
J Clin Oncol
, vol.21
, Issue.16
, pp. 3041-3050
-
-
Doorduijn, J.K.1
Van Der Holt, B.2
Van Imhoff, G.W.3
-
20
-
-
0030964191
-
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma
-
Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood. 1997;89(11):3974-3979.
-
(1997)
Blood
, vol.89
, Issue.11
, pp. 3974-3979
-
-
Zinzani, P.L.1
Pavone, E.2
Storti, S.3
-
21
-
-
0026667676
-
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: A randomized controlled trial
-
Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80(6):1430-1436.
-
(1992)
Blood
, vol.80
, Issue.6
, pp. 1430-1436
-
-
Pettengell, R.1
Gurney, H.2
Radford, J.A.3
-
22
-
-
84863902271
-
Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy
-
Chan KKW, Siu E, Krahn MD, Imrie K, Alibhai SMH. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol. 2012;30(10):1064-1071.
-
(2012)
J Clin Oncol
, vol.30
, Issue.10
, pp. 1064-1071
-
-
Chan, K.K.W.1
Siu, E.2
Krahn, M.D.3
Imrie, K.4
Alibhai, S.M.H.5
-
23
-
-
33645810425
-
Good practice guidelines for decision-analytic modelling in health technology assessment: A review and consolidation of quality assessment
-
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24(4):355-371.
-
(2006)
Pharmacoeconomics
, vol.24
, Issue.4
, pp. 355-371
-
-
Philips, Z.1
Bojke, L.2
Sculpher, M.3
Claxton, K.4
Golder, S.5
-
24
-
-
84881622543
-
-
Accessed August 3, 2011
-
Freedman AS, Aster JC. Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma. www.uptodate. com. Accessed August 3, 2011.
-
Epidemiology, Clinical Manifestations, Pathologic Features, and Diagnosis of Diffuse Large B Cell Lymphoma
-
-
Freedman, A.S.1
Aster, J.C.2
-
25
-
-
2942746370
-
Granulopoiesisstimulating factors to prevent adverse effects in the treatment of malignant lymphoma
-
Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesisstimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev. 2008;4:CD003189.
-
(2008)
Cochrane Database Syst Rev
, vol.4
-
-
Bohlius, J.1
Herbst, C.2
Reiser, M.3
Schwarzer, G.4
Engert, A.5
-
26
-
-
34548789514
-
Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection
-
Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: Effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400-411.
-
(2007)
Ann Intern Med
, vol.147
, Issue.6
, pp. 400-411
-
-
Sung, L.1
Nathan, P.C.2
Alibhai, S.M.3
Tomlinson, G.A.4
Beyene, J.5
-
27
-
-
77956400375
-
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review
-
Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28(17):2914-2924.
-
(2010)
J Clin Oncol
, vol.28
, Issue.17
, pp. 2914-2924
-
-
Lyman, G.H.1
Dale, D.C.2
Wolff, D.A.3
-
28
-
-
85037866482
-
-
Ontario Ministry of Health and Long-Term Care Accessed March 2, 2013
-
Ontario Ministry of Health and Long-Term Care. Ontario Public Drug Programs Formulary. http://www.health.gov.on.ca/english/providers/program/drugs/ odbf-mn.html. Accessed March 2, 2013.
-
Ontario Public Drug Programs Formulary
-
-
-
29
-
-
76249099525
-
Evaluation of direct medical costs of hospitalization for febrile neutropenia
-
Lathia N, Mittmann N, DeAngelis C, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 2010;116(3):742-748.
-
(2010)
Cancer
, vol.116
, Issue.3
, pp. 742-748
-
-
Lathia, N.1
Mittmann, N.2
Deangelis, C.3
-
30
-
-
22444443711
-
Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy
-
Doorduijn J, Buijt I, Holt B, Steijaert M, Uyl-de Groot C, Sonneveld P. Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy. Eur J Haematol. 2005;75(2):116-123.
-
(2005)
Eur J Haematol
, vol.75
, Issue.2
, pp. 116-123
-
-
Doorduijn, J.1
Buijt, I.2
Holt, B.3
Steijaert, M.4
Uyl-De Groot, C.5
Sonneveld, P.6
-
32
-
-
0037313173
-
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma
-
Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol. 2003;21(3):514-519.
-
(2003)
J Clin Oncol
, vol.21
, Issue.3
, pp. 514-519
-
-
Vose, J.M.1
Crump, M.2
Lazarus, H.3
-
33
-
-
17644379037
-
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
-
Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916-1924.
-
(2005)
Cancer
, vol.103
, Issue.9
, pp. 1916-1924
-
-
Caggiano, V.1
Weiss, R.V.2
Rickert, T.S.3
Linde-Zwirble, W.T.4
-
34
-
-
24344445873
-
Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/-Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas
-
Cullen M. Steven N. Billingham L. et al. Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/-Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988-998.
-
(2005)
N Engl J Med
, vol.353
, Issue.10
, pp. 988-998
-
-
Cullen, M.1
Steven, N.2
Billingham, L.3
-
35
-
-
0036532256
-
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis
-
Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406-411.
-
(2002)
Am J Med
, vol.112
, Issue.5
, pp. 406-411
-
-
Lyman, G.H.1
Kuderer, N.M.2
Djulbegovic, B.3
-
36
-
-
33746007143
-
Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer
-
Timmer-Bonte JN, Adang EM, Smit HJ, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24(19):2991-2997.
-
(2006)
J Clin Oncol
, vol.24
, Issue.19
, pp. 2991-2997
-
-
Timmer-Bonte, J.N.1
Adang, E.M.2
Smit, H.J.3
-
37
-
-
33745982067
-
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
-
Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127.
-
(2006)
J Clin Oncol
, vol.24
, Issue.19
, pp. 3121-3127
-
-
Habermann, T.M.1
Weller, E.A.2
Morrison, V.A.3
-
38
-
-
33644554514
-
The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies
-
Cherif H, Johansson E, Bjorkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica. 2006;91(2):215-222.
-
(2006)
Haematologica
, vol.91
, Issue.2
, pp. 215-222
-
-
Cherif, H.1
Johansson, E.2
Bjorkholm, M.3
Kalin, M.4
-
39
-
-
41849097436
-
Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: Feasibility and safety in routine clinical practice
-
Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the multinational association for supportive care in cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008;16(5):485-491.
-
(2008)
Support Care Cancer
, vol.16
, Issue.5
, pp. 485-491
-
-
Innes, H.1
Lim, S.L.2
Hall, A.3
Chan, S.Y.4
Bhalla, N.5
Marshall, E.6
-
40
-
-
33748661910
-
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications
-
Klastersky J, Paesmans M, Georgala A, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol. 2006;24(25):4129-4134.
-
(2006)
J Clin Oncol
, vol.24
, Issue.25
, pp. 4129-4134
-
-
Klastersky, J.1
Paesmans, M.2
Georgala, A.3
-
41
-
-
33846375918
-
-
Bank of Canada Accessed March 2, 2013
-
Bank of Canada. Inflation Calculator. http://www.bankofcanada.ca/rates/ related/inflation-calculator/. Accessed March 2, 2013.
-
Inflation Calculator
-
-
-
42
-
-
0035202991
-
Cost effectiveness of treatment options in advanced breast cancer in the UK
-
Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics. 2001;19(11):1091-1102.
-
(2001)
Pharmacoeconomics
, vol.19
, Issue.11
, pp. 1091-1102
-
-
Brown, R.E.1
Hutton, J.2
Burrell, A.3
-
43
-
-
79959926382
-
Costeffectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the united kingdom
-
Whyte S, Cooper KL, Stevenson MD, Madan J, Akehurst R. Costeffectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the united kingdom. Value Health. 2011;14(4):465-474.
-
(2011)
Value Health
, vol.14
, Issue.4
, pp. 465-474
-
-
Whyte, S.1
Cooper, K.L.2
Stevenson, M.D.3
Madan, J.4
Akehurst, R.5
-
44
-
-
0347985317
-
Chemotherapy-induced neutropenia risks consequences and new directions for its management
-
Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-237.
-
(2004)
Cancer
, vol.100
, Issue.2
, pp. 228-237
-
-
Crawford, J.1
Dale, D.C.2
Lyman, G.H.3
-
45
-
-
0026575912
-
How attractive does a new technology have to be to warrant adoption and utilization Tentative guidelines for using clinical and economic evaluations
-
Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146(4):473-481.
-
(1992)
CMAJ
, vol.146
, Issue.4
, pp. 473-481
-
-
Laupacis, A.1
Feeny, D.2
Detsky, A.S.3
Tugwell, P.X.4
-
46
-
-
65549153613
-
Efficacy does not necessarily translate to cost effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing
-
Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol. 2009;27(13):2111-2113.
-
(2009)
J Clin Oncol
, vol.27
, Issue.13
, pp. 2111-2113
-
-
Hillner, B.E.1
Smith, T.J.2
-
47
-
-
41149171625
-
What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule
-
Braithwaite RS, Meltzer DO, King JT, Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per qualityadjusted life-year decision rule Med Care. 2008;46(4):349-356.
-
(2008)
Med Care
, vol.46
, Issue.4
, pp. 349-356
-
-
Braithwaite, R.S.1
Meltzer, D.O.2
King Jr., J.T.3
Leslie, D.4
Roberts, M.S.5
-
48
-
-
79959745514
-
Use of colony-stimulating factors with chemotherapy: Ppportunities for cost savings and improved outcomes
-
Potosky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: ppportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011;103(12):979-982.
-
(2011)
J Natl Cancer Inst
, vol.103
, Issue.12
, pp. 979-982
-
-
Potosky, A.L.1
Malin, J.L.2
Kim, B.3
-
49
-
-
79957492218
-
Bending the cost curve in cancer care
-
Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060-2065.
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 2060-2065
-
-
Smith, T.J.1
Hillner, B.E.2
-
50
-
-
85081799745
-
-
Amgen Inc Accessed July 23, 2012
-
Amgen Inc. Amgen media news release. http://www.amgen.com/media/media-pr- detail.jspyear=2012&releaseID=1653300. Accessed July 23, 2012.
-
Amgen Media News Release
-
-
|